Characterization of multiple parameters in this model, including in-life proteinuria, terminal kidney histology, autoantibody titers, kidney gene expression and immunophenotyping, were analyzed to better understand the potential mechanism by which S1PR1 and S1PR5 modulation confers efficacy in SLE. This evidence concerns the gene S1PR5 and systemic lupus erythematosus.